Single and Multiple Dose PK–PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers

Carisoprodol was authorised in 1959 without a full pharmacokinetic–pharmacodynamic (PK–PD) characterisation. We designed a crossover, double-blind, placebo-controlled, randomized clinical trial to characterize the PKs of carisoprodol and its main active metabolite, meprobamate, after single (350 mg)...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo, Aitana, Alonso, Saioa, Prieto, Esther, Ascaso-del-Rio, Ana, Ortuño, Jordi, Fernandez, Nieves, Portolés, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836664/
https://www.ncbi.nlm.nih.gov/pubmed/35160309
http://dx.doi.org/10.3390/jcm11030858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836664/
https://www.ncbi.nlm.nih.gov/pubmed/35160309
http://dx.doi.org/10.3390/jcm11030858

Ejemplares similares